ProMIS Neurosciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $3.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors that highlight ProMIS Neurosciences’ promising advancements in their Alzheimer’s research and broader neurodegenerative pipeline. The company is currently progressing its Phase 1b ‘PRECISE-AD’ study of PMN310, an antibody targeting Aβ oligomers, with the final cohort in the enrollment phase. This study has shown positive safety results, with no ARIA events reported, which is a significant concern in similar treatments.
Additionally, ProMIS is advancing other programs, such as PMN267 for ALS and PMN442 for Parkinson’s/MSA, derived from their EpiSelect platform. These developments, along with the company’s financial position, which includes sufficient funding to continue operations into 2026, contribute to the optimistic outlook. The anticipated data readouts in 2026 are expected to be pivotal for the company’s stock performance, supporting McCarthy’s Buy rating.
McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, OS Therapies Incorporated, and Neuphoria Therapeutics. According to TipRanks, McCarthy has an average return of -14.4% and a 33.20% success rate on recommended stocks.